Morgan Stanley’s Royalty Pharma RPRX Stock Holding History

Morgan Stanley’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.41B	Sell	42,931,597 -640,036	-1%	-$33.3M	0.13%	131
2026 Q1	$2.09B	Sell	43,571,633 -11,702,436	-21%	-$513M	0.13%	141
2025 Q4	$2.14B	Buy	55,274,069 +11,110,115	+25%	+$424M	0.13%	136
2025 Q3	$1.56B	Sell	44,163,954 -2,440,149	-5%	-$88.3M	0.09%	189
2025 Q2	$1.68B	Buy	46,604,103 +5,574,271	+14%	+$185M	0.11%	165
2025 Q1	$1.28B	Buy	41,029,832 +1,497,062	+4%	+$47.5M	0.09%	196
2024 Q4	$1.01B	Sell	39,532,770 -1,545,393	-4%	-$41M	0.07%	249
2024 Q3	$1.16B	Sell	41,078,163 -3,055,283	-7%	-$84.6M	0.08%	217
2024 Q2	$1.16B	Sell	44,133,446 -84,439	-0.2%	-$2.34M	0.09%	196
2024 Q1	$1.34B	Sell	44,217,885 -2,136,381	-5%	-$63M	0.11%	179
2023 Q4	$1.3B	Sell	46,354,266 -1,778,349	-4%	-$48.9M	0.11%	166
2023 Q3	$1.31B	Buy	48,132,615 +702,754	+1%	+$20.9M	0.13%	144
2023 Q2	$1.46B	Buy	47,429,861 +79,403	+0.2%	+$2.69M	0.14%	133
2023 Q1	$1.71B	Sell	47,350,458 -1,895,574	-4%	-$70.3M	0.18%	110
2022 Q4	$1.95B	Sell	49,246,032 -940,129	-2%	-$39.2M	0.22%	90
2022 Q3	$2.02B	Sell	50,186,161 -1,357,010	-3%	-$58M	0.27%	71
2022 Q2	$2.17B	Sell	51,543,171 -1,998,617	-4%	-$81.9M	0.28%	71
2022 Q1	$2.09B	Sell	53,541,788 -2,688,902	-5%	-$106M	0.28%	81
2021 Q4	$2.24B	Sell	56,230,690 -1,074,621	-2%	-$41.7M	0.28%	85
2021 Q3	$2.07B	Buy	57,305,311 +6,511,270	+13%	+$253M	0.28%	82
2021 Q2	$2.08B	Buy	50,794,041 +2,675,799	+6%	+$114M	0.27%	79
2021 Q1	$2.1B	Buy	48,118,242 +24,320,161	+102%	+$1.15B	0.31%	69
2020 Q4	$1.19B	Buy	23,798,081 +14,431,463	+154%	+$612M	0.18%	129
2020 Q3	$394M	Buy	9,366,618 +3,161,432	+51%	+$136M	0.08%	226
2020 Q2	$301M	Buy	+6,205,186	New	+$307M	0.07%	259

Other funds holding RPRX

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIA

Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Morgan Stanley's RPRX Position: Q2 2026 in Review

Morgan Stanley reduced its Royalty Pharma (RPRX) stake by 1.5% in Q2 2026, selling an estimated $33.3M and leaving 42,931,597 shares worth $2.41B. The position accounts for 0.13% of the portfolio, ranked #131.

Morgan Stanley first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Morgan Stanley held 42,931,597 shares of Royalty Pharma worth $2.41B as of Q2 2026.
Morgan Stanley sold 640,036 Royalty Pharma shares in Q2 2026, an estimated $33.3M.
Royalty Pharma made up 0.13% of Morgan Stanley's portfolio in Q2 2026, its #131 holding.
Morgan Stanley first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.